By Sandy Vogt, Ph.D.

Every monumental breakthrough in the treatment of type 1 diabetes (T1D) follows a remarkably similar trajectory. It begins as a flicker of an idea—a hypothesis whispered in a laboratory or a concept sketched on a whiteboard. Through years of rigorous research, these ideas transition into something tangible: controlled experiments, massive datasets, and early-stage prototypes. However, for the millions of individuals living with T1D, the bridge between a laboratory success and a pharmacy shelf is often long and fraught with regulatory and financial hurdles.

As we observe National Diabetes Awareness Month, the T1D community has reason to celebrate a historic cadence of progress. The past twelve months have seen a flurry of federal approvals and policy shifts that represent the culmination of decades of advocacy and scientific inquiry. These milestones are not merely incremental updates; they are paradigm-shifting developments that redefine what it means to live with, and eventually treat, an autoimmune condition that has long demanded 24/7 vigilance.

From the democratization of insulin pricing to the first-ever therapies capable of delaying the onset of the disease, the following chronology outlines a year of unprecedented achievement in the T1D landscape.

Table of Contents

The Chronology of Progress: A Month-by-Month Breakdown

The progress seen over the last year spans the entire spectrum of T1D care, including affordability, disease modification, technological integration, and the management of long-term complications.

January: Breaking the Cost Barrier for Long-Acting Insulin

The year began with a significant victory in the realm of healthcare equity and access. In January, Civica announced that its long-acting insulin glargine-yfgn—a biosimilar interchangeable with the widely used Lantus—would be available for no more than $55 for a pack of five pens.

For decades, the soaring cost of insulin has been a point of national crisis, forcing many patients to ration a life-sustaining hormone. The Civica initiative is groundbreaking because it is available to anyone with a prescription, regardless of their insurance status. By decoupling the price of insulin from complex insurance negotiations, this move sets a new standard for pharmaceutical transparency and ensures that the financial burden of T1D does not dictate a patient’s health outcomes.

April: The Dawn of Disease Modification with Teplizumab (Tzield)

In April, a landmark approval transformed the way clinicians approach the early stages of T1D. The FDA expanded the use of teplizumab (marketed as Tzield) for children aged one and older who are in Stage 2 T1D. Stage 2 is characterized by the presence of two or more diabetes-related autoantibodies and abnormal blood sugar levels, though the patient is still asymptomatic.

Teplizumab is an immunotherapy that works by "re-training" the immune system to stop attacking insulin-producing beta cells. For the first time in history, families can delay the progression to Stage 3 (symptomatic) T1D by an average of two years. These two years represent a "gift of time"—a period where a child can live without the grueling demands of finger sticks, pump sites, and constant carbohydrate counting.

May: Technological Leaps for Pregnancy and Pediatric Care

May saw a dual victory for T1D technology. First, Tandem’s Control-IQ+ became the first automated insulin delivery (AID) system approved specifically for use during pregnancy. Managing T1D while pregnant is an extraordinary challenge, as hormonal shifts cause unpredictable insulin resistance, posing risks to both mother and fetus. The approval of Control-IQ+ provides soon-to-be mothers with an algorithmic safety net, increasing "time in range" and reducing the mental load of constant adjustments.

Simultaneously, the FDA approved Afrezza, a rapid-acting inhaled mealtime insulin, for children and adolescents aged six and older. For many pediatric patients, "needle fatigue" is a significant psychological barrier to effective management. Afrezza offers a non-invasive alternative to traditional injections or pumps, providing families with more flexibility in how they manage post-meal glucose spikes.

June: Addressing the Root Cause in Newly Diagnosed Youth

Building on the momentum of April, June brought further validation for teplizumab (Tzield). The therapy received approval for children and adolescents aged 8 to 17 who are within eight weeks of a Stage 3 T1D diagnosis.

This is a milestone for two reasons: it is the first therapy for Stage 3 T1D that addresses the underlying autoimmune cause rather than just treating the symptoms. Furthermore, it marked the first time regulators approved a T1D therapy based on C-peptide levels—a critical biomarker of the body’s ability to produce its own insulin. By preserving beta-cell function even after diagnosis, patients may experience an easier-to-manage "honeymoon phase" and a lower risk of long-term complications.

August: The Integration of Glucose and Ketone Monitoring

In August, Abbott’s Libre Duo 10 Day received approval as the first device in the United States capable of simultaneously monitoring glucose and ketones. While continuous glucose monitors (CGMs) have become the gold standard of care, ketone monitoring has historically remained a reactive process, often involving painful finger pricks or unreliable urine strips during illness.

Continuous Ketone Monitoring (CKM) is a proactive safeguard against Diabetic Ketoacidosis (DKA), a life-threatening condition caused by a lack of insulin. By providing real-time alerts for rising ketone levels, the Libre Duo allows patients to intervene hours before a metabolic crisis occurs, potentially saving thousands of emergency room visits annually.

September: A Thirty-Year Wait Ends for Kidney Care

The final major milestone of the year arrived in September with the approval of finerenone (brand name Kerendia) for people living with both T1D and chronic kidney disease (CKD).

For three decades, the T1D community had seen little innovation in the treatment of kidney complications, which remain one of the most common and devastating long-term effects of the disease. Finerenone works by blocking mineralocorticoid receptor overactivation, which is thought to contribute to kidney inflammation and fibrosis. This approval provides a vital new tool in the quest to help T1D patients live longer, healthier lives without the looming threat of dialysis or transplant.

Supporting Data: The Burden of T1D and the Impact of Innovation

The significance of these breakthroughs is best understood through the lens of the current T1D landscape. It is estimated that approximately 2 million Americans live with T1D, a number that is projected to grow to 5 million by 2050.

The economic and physical toll is staggering:

Economic Impact: The total cost of diagnosed diabetes in the U.S. is over $400 billion annually.
The "Invisible" Work: A person with T1D makes an average of 180 additional health-related decisions every day compared to a person without the condition.
The Complication Risk: Despite improvements in care, individuals with T1D remain at higher risk for retinopathy, neuropathy, and cardiovascular disease.

The advancements of the past year directly target these statistics. For example, the delay of T1D onset via teplizumab isn’t just a clinical victory; it is an economic one, potentially deferring the high costs of insulin and supplies for years. Similarly, the approval of finerenone addresses one of the most expensive complications—end-stage renal disease—head-on.

Official Responses: Voices from the Frontlines

The leadership at Breakthrough T1D (formerly JDRF) has been vocal about the importance of these milestones. Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, emphasized the emotional weight of the teplizumab approval:

"Intervening earlier and slowing the disease’s progression will provide the gift of time to young children and their caregivers, potentially improving lifelong outcomes. I am immensely proud of Breakthrough T1D’s role in advancing the research that made Tzield possible."

The impact of technology was echoed by patients like Liz Walsh, who has lived with T1D for 35 years and utilized the Tandem Control-IQ+ system during her pregnancy.

"During pregnancy, Control-IQ+ was a game-changer. It helped me achieve more time in range… It also reduced much of the mental burden and T1D-related anxiety… allowing me to focus more on my overall health and my baby’s well-being."

From a research perspective, Joshua Vieth, Ph.D., Senior Director of Research, noted that the June approval of teplizumab for Stage 3 was a "key priority," while Jonathan Rosen, Ph.D., highlighted the "huge win" of finerenone for the community, noting the scarcity of previous treatments for kidney complications.

Implications: From Management to Modification

The overarching theme of the past year is a fundamental shift in the philosophy of T1D care. For a century—since the discovery of insulin in 1921—the focus has been almost entirely on management: how to replace the missing hormone as safely as possible.

The breakthroughs of 2024 signal a transition toward modification and prevention. We are no longer just reacting to high and low blood sugars; we are beginning to interfere with the immune system’s attack on the pancreas and proactively protecting the organs most vulnerable to damage.

However, the work is far from over. While these approvals are monumental, they are only effective if they reach the people who need them. This requires continued advocacy for insurance coverage, global distribution, and public awareness.

Breakthrough T1D has played a pivotal role in every advancement listed in this report, serving as the bridge between donor funding and clinical reality. As we look toward the next year, the focus remains clear: funding essential research into biological cures while simultaneously refining the treatments and devices that improve daily life.

The "ideas" of tomorrow are already in the labs. Some involve stem cell-derived beta cell replacement; others involve "smart" insulins that only activate when blood sugar is high. If the past year is any indication, the distance between those ideas and a reality for the T1D community is shrinking faster than ever before. We are not just managing a disease; we are systematically dismantling it, one breakthrough at a time.